Rahul Rama Hegde

Rahul Rama Hegde

Auto-generated profile, based on publicly available information

Rahul Rama Hegde

C Department of Pharmaceutics , School of Pharmaceutical Sciences, IFTM University Moradabad , Uttar Pradesh , India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Alka LohaniAlka Lohani
Alka Lohani
GSGarima Singh
Garima Singh
SBShiv Sankar Bhattacharya
Shiv Sankar Bhattacharya
RHRahul Rama Hegde
Rahul Rama Hegde
AVAnurag Verma
Anurag Verma

27 June 2013 in ISRN Pharmaceutics
Verified
Journal Article
Open access
PDF file
RHRahul Rama Hegde
Rahul Rama Hegde
AVAnurag Verma
Anurag Verma
AGAmitava Ghosh
Amitava Ghosh
Delivery of drugs into eyes using conventional drug delivery systems, such as solutions, is a considerable challenge to the treatment of ocular diseases. Drug loss from the ocular surface by lachrymal fluid secretion, lachrymal fluid-eye barriers, and blood-ocular barriers are main obstacles. A number of ophthalmic drug delivery carriers have been made to improve the bioavailability and to prolong the residence time of drugs applied topically onto the eye. The potential use of microemulsions as an ocular drug delivery carrier offers several favorable pharmaceutical and biopharmaceutical properties such as their excellent thermodynamic stability, phase transition to liquid-crystal state, very low surface tension, and small droplet size, which may result in improved ocular drug retention, extended duration of action, high ocular absorption, and permeation of loaded drugs. Further, both lipophilic and hydrophilic characteristics are present in microemulsions, so that the loaded drugs can diffuse passively as well get significantly partitioned in the variable lipophilic-hydrophilic corneal barrier. This review will provide an insight into previous studies on microemulsions for ocular delivery of drugs using various nonionic surfactants, cosurfactants, and associated irritation potential on the ocular surface. The reported in vivo experiments have shown a delayed effect of drug incorporated in microemulsion and an increase in the corneal permeation of the drug.

14 August 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PRPriyanka Rani
Priyanka Rani
DPDilipkumar Pal
Dilipkumar Pal
RHRahul Rama Hegde
Rahul Rama Hegde
SHSyed Riaz Hashim
Syed Riaz Hashim
The aphorism was to develop new chemical entities as potential anticancer, anti-inflammatory, and analgesic agents. The Leuckart synthetic pathway was utilized in development of novel series of 2-(substituted phenoxy)-N-(1-phenylethyl)acetamide derivatives. The compounds containing 1-phenylethylamine as basic moiety attached to substituted phenols were assessed for their anticancer activity against MCF-7 (breast cancer), SK-N-SH (neuroblastoma), anti-inflammatory activity, and analgesic activity. These investigations revealed that synthesized products3a–jwith halogens on the aromatic ring favors as the anticancer and anti-inflammatory activity. Among all, compound3cN-(1-(4-chlorophenyl)ethyl)-2-(4-nitrophenoxy)acetamide exhibited anticancer, anti-inflammatory, and analgesic activities. In conclusion,3cmay have potential to be developed into a therapeutic agent.

1 December 2013 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SBShiv Sankar Bhattacharya
Shiv Sankar Bhattacharya
SBSubham Banerjee
Subham Banerjee
PCPurojit Chowdhury
Purojit Chowdhury
AGAmitava Ghosh
Amitava Ghosh
RHRahul Rama Hegde
Rahul Rama Hegde
RMRanjit Mondal
Ranjit Mondal

3 July 2016 in Journal of Chemotherapy
Verified
Journal Article
Closed access
PRPriyanka Rani
Priyanka Rani
DPDilipkumar Pal
Dilipkumar Pal
RHRahul Rama Hegde
Rahul Rama Hegde
SHSyed Riaz Hashim
Syed Riaz Hashim
Now clear evidences are available to support the hypothesis that inflammation accelerates the conditions including events and molecules that reach to various types of cancers. Inflammation is a normal response to infection containing the innate and adaptive immune systems. However, when allowed to continue, unresolved, perturbation of cellular microenvironment takes place; therefore, it leads to adaptations in genes that are linked to cancer. In addition, a lot of data are accessible confirming the concept that tumour microenvironment is orchestrated by various inflammatory cells and goes to neoplastic process and finally invasion, migration and metastasis. However, infiltrations of leucocytes lead to angiogenesis, propagation and invasion. An inflammatory microenvironment that perhaps fostering impact of angiogenesis include cytokines, chemokines, enzymes and growth factors that play key role for expansion and invasion of cancer cells. This insight highlights the pathogenesis of inflammation-associated cancers and also touches and fosters the role of acetamides for the treatment and chemoprevention of carcinomas that are allied with inflammation.

27 March 2016 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
AVAnurag Verma
Anurag Verma
JDJuhi Dubey
Juhi Dubey
RHRahul Rama Hegde
Rahul Rama Hegde
VRVaibhav Rastogi
Vaibhav Rastogi
JPJayanta K Pandit
Jayanta K Pandit
H. pylori have been subject to intense investigation since its discovery from gastric biopsy in 1982. This gastropathogen has been regarded as serious public health problem due to its association with dyspepsia, gastritis, gastroduodenal ulcers, mucus-associated lymphoid tissue lymphoma and gastric carcinoma. In vivo eradication of established H. pylori infections is difficult due to several factors such as gastric niche, coccoid form due to sub minimum inhibitory concentration of antimicrobials, bacterial load, primary antibiotic resistance, patient compliance and stability of therapeutics in gastric acid secretion. Considering these factors, a logical way to improve the outcome of the treatment is to develop dosage forms which are able to deliver the anti-helicobacter agents in the gastric niche for both local and systemic action, simultaneously taking care of stability of therapeutics in acidic environment. Such dosage forms, which are popularly known as gastro retentive drug delivery systems (GRDDS), have the immense potential to effectively counter the problem of high bacterial load; prevent induction of coccoid bacteria thereby improving treatment outcome and compliance. This review describes efficacy of various therapeutic agents, treatment strategies and status of different GRDDS until now.